Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Jacqueline Vuky, John McCaffrey, Michelle Ginsberg, Tania Mariani, Dean F. Bajorin, George J. Bosl, Robert J. Motzer

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126, 000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours.

Original languageEnglish (US)
Pages (from-to)265-267
Number of pages3
JournalInvestigational New Drugs
Volume18
Issue number3
DOIs
StatePublished - 2000

Keywords

  • Cisplatin-refractory
  • Germ cell tumor
  • Pyrazoloacridine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors'. Together they form a unique fingerprint.

Cite this